TSX: HSM     OTC: HSDT

Call us: +1 877-564-0008

divisionBanner

A division of Helius Medical Technologies (Helius), NeuroHabilitation is developing a breakthrough technology as a potential treatment for neurological symptoms caused by disease or trauma.

In 2013, NeuroHabilitation signed a Collaborative Research and Development Agreement (CRADA) with the US Department of Defense to support the clinical, commercial and regulatory development of the PoNS™ technology.

The PoNSTM Device

The PoNS™ device delivers translingual neurostimulation (TLNS) to potentially alter the capacity, organization and function of brain structures.

Learn About The PoNS™ Device